TY - JOUR
T1 - Short Androgen Suppression and Radiation Dose Escalation for Intermediate- and High-Risk Localized Prostate Cancer
T2 - Results of EORTC Trial 22991
AU - Bolla, Michel
AU - Maingon, Philippe
AU - Carrie, Christian
AU - Villa, Salvador
AU - Kitsios, Petros
AU - Poortmans, Philip M. P.
AU - Sundar, Santhanam
AU - van der Steen-Banasik, Elzbieta M.
AU - Armstrong, John
AU - Bosset, Jean-Francois
AU - Herrera, Fernanda G.
AU - Pieters, Bradley
AU - Slot, Annerie
AU - Bahl, Amit
AU - Ben-Yosef, Rahamim
AU - Boehmer, Dirk
AU - Scrase, Christopher
AU - Renard, Laurette
AU - Shash, Emad
AU - Coens, Corneel
AU - van den Bergh, Alphonsus C. M.
AU - Collette, Laurence
PY - 2016/5/20
Y1 - 2016/5/20
N2 - PurposeUp to 30% of patients who undergo radiation for intermediate-or high-risk localized prostate cancer relapse biochemically within 5 years. We assessed if biochemical disease-free survival (DFS) is improved by adding 6 months of androgen suppression (AS; two injections of every-3-months depot of luteinizing hormone-releasing hormone agonist) to primary radiotherapy (RT) for intermediate-or high-risk localized prostate cancer.Patients and MethodsA total of 819 patients staged: (1) cT1b-c, with prostate-specific antigen (PSA) >= 10 ng/mL or Gleason >= 7, or (2) cT2a (International Union Against Cancer TNM1997), with no involvement of pelvic lymph nodes and no clinical evidence of metastatic spread, with PSAResultsThe median patient age was 70 years. Among patients, 74.8% were intermediate risk and 24.8% were high risk. In the RT arm, 407 of 409 patients received RT; in the RT plus AS arm, 403 patients received RT plus AS and three patients received RT only. At 7.2 years median follow-up, RT plus AS significantly improved biochemical DFS (HR, 0.52; 95% CI, 0.41 to 0.66; PConclusionSix months of concomitant and adjuvant AS improves biochemical and clinical DFS of intermediate- and high-risk cT1b-c to cT2a (with no involvement of pelvic lymph nodes and no clinical evidence of metastatic spread) prostatic carcinoma, treated by radiation.
AB - PurposeUp to 30% of patients who undergo radiation for intermediate-or high-risk localized prostate cancer relapse biochemically within 5 years. We assessed if biochemical disease-free survival (DFS) is improved by adding 6 months of androgen suppression (AS; two injections of every-3-months depot of luteinizing hormone-releasing hormone agonist) to primary radiotherapy (RT) for intermediate-or high-risk localized prostate cancer.Patients and MethodsA total of 819 patients staged: (1) cT1b-c, with prostate-specific antigen (PSA) >= 10 ng/mL or Gleason >= 7, or (2) cT2a (International Union Against Cancer TNM1997), with no involvement of pelvic lymph nodes and no clinical evidence of metastatic spread, with PSAResultsThe median patient age was 70 years. Among patients, 74.8% were intermediate risk and 24.8% were high risk. In the RT arm, 407 of 409 patients received RT; in the RT plus AS arm, 403 patients received RT plus AS and three patients received RT only. At 7.2 years median follow-up, RT plus AS significantly improved biochemical DFS (HR, 0.52; 95% CI, 0.41 to 0.66; PConclusionSix months of concomitant and adjuvant AS improves biochemical and clinical DFS of intermediate- and high-risk cT1b-c to cT2a (with no involvement of pelvic lymph nodes and no clinical evidence of metastatic spread) prostatic carcinoma, treated by radiation.
KW - QUALITY-OF-LIFE
KW - RANDOMIZED CONTROLLED-TRIAL
KW - PHASE-III TRIAL
KW - RADIOTHERAPY
KW - THERAPY
KW - ONCOLOGY
KW - DEPRIVATION
KW - RTOG
KW - DURATION
U2 - 10.1200/JCO.2015.64.8055
DO - 10.1200/JCO.2015.64.8055
M3 - Article
SN - 0732-183X
VL - 34
SP - 1748
EP - 1756
JO - Journal of Clinical Oncology
JF - Journal of Clinical Oncology
IS - 15
ER -